Medical Cannabis Rescheduling: The initial breakdown

Here’s what we know so far about the new federal medical cannabis / DEA rescheduling framework, the June 22 date, fees, federal grants, and 280E—with the important caveat that IRS/SBA implementation details are still developing.

What is the June 22 DEA filing deadline?

On April 22, 2026, the DOJ/DEA issued a final order that moves:

• FDA‑approved marijuana products, and

• Marijuana is handled under a qualifying state medical marijuana license

from Schedule I to Schedule III of the CSA, effective immediately.

For state‑licensed medical operators, DEA is creating an expedited registration pathway:

• State medical marijuana licensees that submit a DEA registration application within 60 days of publication (by Monday, June 22, 2026) can continue operating under their state license while the DEA reviews the application.

• DEA has committed to processing those “early” applications within six months.

So, for a Minnesota‑style state medical operator, June 22, 2026 is the priority window to:

• File the appropriate DEA registration (manufacturer/distributor/dispenser)

• Lock in the ability to operate during review rather than having to pause operations under federal law.

Initial and ongoing DEA fees

DEA is applying its standard Schedule III registration fee structure to these medical cannabis registrations.

Current fees are:

• Manufacturer (cultivator/processor in DEA terms):

  • $3,699 annually. Also, there is a $113 per kilogram (each 35.5lbs)

• Distributor:

  • $1,850 annually.

• Dispenser (includes pharmacies and, under this order, medical dispensaries):

  • $888 for a three‑year registration (effectively ~$296/year).

Key points:

• These are federal DEA fees only; they’re in addition to existing state application/license/renewal fees.

• As of now, no separate “one‑time” DEA application fee is described beyond the standard registration fee; the recurring fee is the main cost structure.

• For security/storage, DEA allows state‑licensed medical operators to meet Schedule III security obligations by complying with their state security standards, rather than stricter standalone federal build‑outs, which is a cost saver.

Can medical cannabis operators use federal grants?

A. General federal small‑business grants/loans

The current federal posture is still restrictive:

• The Small Business Administration (SBA) updated guidance in 2025 explicitly stating that businesses that “grow, produce, process, distribute, or sell marijuana” are ineligible for key loan programs like 7(a) and 504.

• That guidance is framed broadly as “marijuana businesses,” and has not yet been revised to carve out state‑licensed medical operators under Schedule III.

So as of now:

• Traditional SBA loans and many SBA‑linked federal financing tools remain off‑limits to plant‑touching cannabis businesses, even medical.

• Most general federal small‑business grants/loan guarantees follow similar controlled‑substance exclusions in their program rules, and those rules have not yet been systematically updated to reflect the April 2026 DOJ/DEA order.

B. Specialized or state‑administered grants

• Several states run cannabis‑specific grant or loan programs (e.g., New Jersey’s Cannabis Business Development Grant, which reimburses up to $75,000 for eligible cannabis businesses).

• These are state programs funded and structured under state law; they are distinct from federal grants, and typically are available to licensed cannabis operators.

Bottom line on grants right now:

• Plant‑touching medical cannabis businesses should not assume eligibility for federal grants or SBA‑style loans yet.

• State or local cannabis‑specific grant/loan programs may be available, and those are where the near‑term opportunity lies.

• Over the next 12–24 months, watch for program‑by‑program rule changes—Congress or agencies could start carving out DEA‑registered medical operators, but that has not happened broadly yet.

Can medical cannabis bypass IRC 280E now?

This is the biggest immediate win for medical operators.

A. Why 280E no longer applies to qualifying medical cannabis

• IRC 280E disallows deductions and credits for businesses that “traffic in controlled substances” listed on Schedule I or II of the CSA.

• Moving a substance to Schedule III means it is no longer within the scope of 280E, because 280E only references Schedules I and II.

The April 22, 2026 DOJ/DEA order explicitly:

• Places FDA‑approved cannabis products and state‑licensed medical marijuana products into Schedule III.

• Legal and tax analysis since the order is clear: state‑licensed medical cannabis operators are no longer subject to §280E’s deduction disallowance for those Schedule III activities.

Implications:

• Medical operators can now deduct ordinary and necessary business expenses (rent, payroll, marketing, admin, etc.) at the federal level, like any other Schedule III business.

• This is a major effective‑tax‑rate reduction compared to the prior 280E treatment.

B. Does DEA registration matter for 280E?

Some tax and regulatory commentary flags a nuance:

• The rescheduling order does not clearly state that medical marijuana handled by a non‑DEA registrant is still Schedule I, but the IRS could take the position that 280E continues to apply to operators who do not obtain DEA registration, at least until guidance is clarified.

• Several firms are recommending that state‑licensed medical operators file for DEA registration (by June 22 if possible), both for compliance and to strengthen the case that their activities are unequivocally Schedule III.

So from a risk‑management perspective:

• To truly “bypass 280E” in a durable way, a state medical operator should:

  • Be operating under a qualifying state medical program, and

  • Apply for and maintain DEA Schedule III registration appropriate to its role (manufacturer/distributor/dispenser).

  • 
    

C. Adult‑use still stuck under 280E

• The order does not reclassify adult‑use cannabis; anything outside FDA‑approved products and qualifying state medical programs remains Schedule I.

• Adult‑use operators, therefore, remain subject to 280E until and unless DEA reschedules “marijuana as a whole” after the June 29, 2026, hearing and any follow‑on rulemaking.

For mixed operators:

• Expect a need to segregate medical vs adult‑use operations, accounting, and entity structure if you want to clearly isolate non‑280E medical revenue from still‑280E adult‑use revenue.

WHAT TO DO? Practical takeaways for you (as an advisor/operator)

For a state‑license medical operator (existing or planned):

• File the DEA registration before June 22, 2026

  • Choose the correct category:

    • Cultivation/processing → Manufacturer

    • Distribution/wholesale logistics → Distributor

    • Retail dispensary → Dispenser.

  • Filing by June 22 lets you keep operating under state law while DEA processes, with a six‑month processing commitment.

• Budget for DEA fees and ongoing compliance

  • Manufacturer: $3,699/year

  • Distributor: $1,850/year

  • Dispenser: $888 per 3 years.

  • Leverage the rule that state security standards satisfy federal security to avoid overbuilding.

• Plan for 280E relief

  • Work with tax counsel to:

    • Model the impact of fully deductible OPEX under Schedule III.

    • Evaluate amended returns for open years where possible.

    • Design entity/accounting structures that separate medical from adult‑use if you’re dual‑licensed.

• Be conservative about federal grants/loans

  • Assume SBA and many federal programs still treat cannabis as ineligible until official revisions say otherwise.

  • Focus near‑term on state or local equity/cannabis‑specific grant/loan programs.

• Monitor the June 29, 2026, DEA hearing

  • That proceeding will address potential broader rescheduling of marijuana as a whole to Schedule III, which could eventually extend 280E relief and banking/grant changes to adult‑use as well.